Ardent biopharmaceutical entrepreneur with a proven track record in biologics drug development from early R&D and product design stages through commercial launch, in building out and leading Preclinical R&D and Technical Operations/Pharmaceutical Sciences teams, in evaluating & negotiating in-licensed biologics drugs and successfully co-leading Series A/B fundraising Extensive multi-disciplinary leadership experience in biologics drug discovery & preclinical development, GLP/non-GLP pharmacology & toxicology, non-clinical/CMC regulatory strategy, Quality management systems (QMS), commercial cost of goods sold (COGS) analysis & supply chain management, product and portfolio IP strategy, and CRDO/CDMO contract negotiations and management.Proficient in building out high-throughput platforms for biologic drug candidate production & screening and complex biologic drug design & engineering, including bispecific antibodies, antibody drug conjugates and fusion proteinsEstablished cost-effective and fast-to-clinic antibody discovery & development platforms including lead candidate selection, antibody engineering, high-throughput functional/developability assays screens, non-clinical pharmacology & toxicology assessments and rapid CMC development/manufacturing for IND and post-IND submissionsCurrently raising seed funding for establishing a novel hub-and-spoke platform of biologic drugs:­- Building a clinical stage company to rapidly establish a portfolio of highly-differentiated biologic drugs for auto-immune and inflammatory diseases­- Setting up a company to establish oral delivery of validated biologics in human clinical studies